Key Factors Fueling the Growth of the Pernicious Anemia Diagnosis And Treatment Market in 2025: Rising Prevalence Of Vitamin B12 Deficiency Fueling Growth In The Market Due To Shifting Dietary Patterns And Aging Population
We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Are the Key Projections for the CAGR of the Pernicious Anemia Diagnosis And Treatment Market Size From 2025 to 2034?
The market size for diagnosing and treating pernicious anemia has seen substantial growth in recent years. The market is projected to increase from $1.42 billion in 2024 to $1.52 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.0%. This notable growth during the historic period can be linked to heightening awareness of vitamin B12 deficiency, the increasing occurrence of autoimmune diseases, a rise in the elderly population, enhanced training for physicians on anemia, and the accessibility of oral and injectable vitamin B12.
The market size for diagnosis and treatment of pernicious anemia is projected to exhibit robust growth in the forthcoming years, escalating to $1.97 billion by 2029 with a compound annual growth rate (CAGR) of 6.8%. This anticipated growth during the forecast period is primarily driven by expanding telemedicine services, increasing demand for early diagnosis, a heightened emphasis on personalized medicine, government-led screening initiatives, and a surge in patient’s inclination towards non-invasive treatments. Key trends during the forecast period encompass the evolution of long-acting vitamin B12 preparations, escalating utilization of diagnostic kits at home, incorporation of artificial intelligence (AI) in anemia detection, burgeoning digital health monitoring tools, and innovations in diagnostic technologies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24360&type=smp
What are the Fundamental Drivers and Innovations Shaping the Pernicious Anemia Diagnosis And Treatment Market?
Growth in the pernicious anemia diagnosis and treatment market is anticipated due to the increasing occurrence of vitamin B12 deficiency. This deficiency happens when the body does not have enough of the vitamin to generate sufficient red blood cells, leading to symptoms such as neurological issues, fatigue, and weakness. The increase in vitamin B12 insufficiency is a byproduct of the rising dominance of plant-based diets which often don’t provide enough natural B12 sources, leading to inadequate intake unless properly supplemented. Vitamin B12 insufficiency bolsters pernicious anemia investigation and treatment as diminished B12 levels immediately inhibit the manufacturing of red blood cells. This prompts physicians to employ B12 supplementation as a leading and effective treatment method. For instance, a report released by the UK-based National Health Service (NHS) in February 2023 revealed that vitamin B12 and folate deficiencies are more widespread among the elderly, affecting approximately 1 in 10 individuals aged 75 and above, and 1 in 20 of those aged 65 to 74. Hence, the increasing prevalence of vitamin B12 insufficiency is propelling the growth of the pernicious anemia diagnosis and treatment market.
How Is the Pernicious Anemia Diagnosis And Treatment Market Segmented?
The pernicious anemia diagnosis and treatment market covered in this report is segmented –
1) By Type: Complete Blood Count Test, Vitamin B12 Deficiency test, Intrinsic Factor Deficiency Test
2) By Treatment: Vitamin B12 Injections, Vitamin B12 Pills, Spray
3) By Route Of Administration: Injection, Oral, Intranasal
4) By End-User: Hospitals, Clinics, Diagnostic Centres, Other End-users
Subsegments:
1) By Complete Blood Count (CBC) Test: Red Blood Cell Count, Hemoglobin Concentration, Hematocrit Levels, Mean Corpuscular Volume (MCV), White Blood Cell Count, Platelet Count
2) By Vitamin B12 Deficiency Test: Serum Vitamin B12 Test, Methylmalonic Acid (MMA) Test, Homocysteine Test, Holotranscobalamin (Active B12) Test
3) By Intrinsic Factor Deficiency Test: Intrinsic Factor Antibody Test, Parietal Cell Antibody Test, Schilling Test, Gastrin Level Test
Request customized data on this market:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24360&type=smp
Which Regions Are Driving the Next Phase of the Pernicious Anemia Diagnosis And Treatment Market Growth?
North America was the largest region in the pernicious anemia diagnosis and treatment market in 2024. The regions covered in the pernicious anemia diagnosis and treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Pernicious Anemia Diagnosis And Treatment Market?
Pioneering businesses in the pernicious anemia diagnosis and treatment market are concentrating on devising inventive solutions like vitamin B12 maintenance therapy methods to heighten patient compliance and enduring disease management. Vitamin B12 maintenance therapy methods comprise consistent supplementation via oral tablets, injections, or nasal sprays to ensure suitable B12 levels and prevent the resurgence of deficiency-related symptoms. Lupin Pharmaceuticals Inc., a pharmaceutical company based in India, introduced a cyanocobalamin nasal spray, 500 mcg/spray in February 2024 – a less invasive option for vitamin B12 supplementation. This nasal spray offers an accessible and effective solution for patients with pernicious anemia who find difficulties with oral vitamin B12 forms. It aids in enhancing B12 absorption and contributes to the management of vitamin B12 deficiency, ultimately boosting patient adherence and treatment results.
View the full report here:
How Is the Pernicious Anemia Diagnosis And Treatment Market Defined and What Are Its Core Parameters?
Pernicious anemia diagnosis and treatment refers to the process of identifying and managing a condition where the body cannot produce enough healthy red blood cells due to impaired absorption of vitamin B12, often linked to the absence of intrinsic factor. Diagnosis involves assessing clinical symptoms such as fatigue, weakness, and neurological disturbances. Treatment focuses on restoring vitamin B12 levels to promote normal red blood cell production, relieve symptoms, and prevent long-term health complications.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/customise?id=24360&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
